A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: Pretreatment impacts survival

Annals of Oncology

Volumn 26, Issue 3, 2015, Pages 573-582

  Ugurel, Selma ^a,b   Loquai, C ^c   Kahler K ^d   Hassel, J ^e   Berking, C ^f   Zimmer, L ^a   Haubitz, I ^b   Satzger, I ^g   Muller Brenne T ^c   Mikhaimer, N C ^d   Becker, J C ^h   Kilian, K J ^f   Schadendorf, D ^a   Heinzerling, L ⁱ   Kaatz, M ^j,k   Utikal, J ^l   Goppner D ^m   Pfohler C ⁿ   Pflugfelder, A ^o   Mossner R ^p   Gutzmer, R ^g   more..

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d UNIVERSITY OF KIEL   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^g HANNOVER MEDICAL SCHOOL   (Germany)

^h MEDICAL UNIVERSITY OF GRAZ   (Austria)

ⁱ UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^j SRHWaldklinikum Gera ^*  (Germany)

^k FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^l UNIVERSITY OF HEIDELBERG   (Germany)

^m OTTO VON GUERICKE UNIVERSITY   (Germany)

ⁿ SAARLAND UNIVERSITY   (Germany)

^o UNIVERSITY OF TÜBINGEN   (Germany)

^p UNIVERSITY OF GÖTTINGEN   (Germany)

more..

Author keywords

BRAF inhibition; Melanoma; Predictive factors; Therapy outcome; Vemurafenib

Indexed keywords

B RAF KINASE; LACTATE DEHYDROGENASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; SORAFENIB; VEMURAFENIB; INDOLE DERIVATIVE; SULFONAMIDE;

ADULT; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS; FEMALE; FOLLOW UP; FUNCTIONAL STATUS ASSESSMENT; GENE MUTATION; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; SKIN METASTASIS; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MIDDLE AGED; MULTICENTER STUDY; SKIN NEOPLASMS; TREATMENT OUTCOME;

ADULT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDOLES; MALE; MELANOMA; MIDDLE AGED; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84941636627     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu573     Document Type: Article

References (20)

1. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. NEJM 2011; 364: 2517-2526.
2. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. NEJM 2011; 364: 2507-2516.
3. Hauschild A, Grob JJ, Demidov LV et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380: 358-365.
4. Flaherty KT, Robert C, Hersey P et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367: 107-114.
5. Weber JS, Kudchadkar RR, Yu B et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or-naive melanoma. J Clin Oncol 2013; 31: 4311-4318.
6. Balch CM, Gershenwald JE, Soong SJ et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-6206.
7. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216.
8. Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics 1982; 38: 29-41.
9. Larkin J, Del VM, Ascierto PA et al. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol 2014; 15: 436-444.
10. Goldinger SM, Zimmer L, Schulz C et al. Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients. Eur J Cancer 2014; 50: 406-410.
11. Ackerman A, Klein O, McDermott DF et al. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer 2014; 120: 1695-1701.
12. Ascierto PA, Simeone E, Sileni VC et al. Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program. Cancer Invest 2014; 32: 144-149.
13. Sosman JA, Kim KB, Schuchter L et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366: 707-714.
14. McArthur GA, Chapman PB, Robert C et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014; 15: 323-332.
15. Becker JC, Andersen MH, Hofmeister-Muller V et al. Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma. Cancer Immunol Immunother 2012; 61: 2091-2103.
16. Hill GJ, Krementz ET, Hill HZ. Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. Cancer 1984; 53: 1299-1305.
17. Menzies AM, Haydu LE, Visintin L et al. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res 2012; 18: 3242-3249.
18. Larkin J, Ascierto PA, Dréno B et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014; 371: 1867-1876.
19. Robert C, Karaszewska B, Schachter J et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. NEJM 2014; 372: 30-39.
20. Long GV, Stroyakovskiy D, Gogas H et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014; 371:1877-1888.